A Phase 2 interventional study of Guselkumab and Placebo in Giant Cell Arteritis, sponsored by Janssen Research & Development, LLC. Terminated at 30 sites in 9 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Giant Cell Arteritis with a site in Italy — 1 open to participants now, 1 under way, none of them phase 3. Giant Cell Arteritis · Italy.
Among the 12 studies in Giant Cell Arteritis with a site in Italy, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 2 in phase 2, and was the 9th registered.
149 studies on the registry are indexed under Giant Cell Arteritis; 50 are open to participants now.
Browse Giant Cell Arteritis studies →1 of the 12 studies in Giant Cell Arteritis with a site in Italy is open now. Recruiting first, the newest first:
ASST Fatebenefratelli Sacco · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 64 across 65 interventional studies indexed under Giant Cell Arteritis.
Median enrollment 77 across the 10 interventional studies, 2,175 across the 2 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 2 studies filed under Giant Cell Arteritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Giant Cell Arteritis with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the efficacy of guselkumab compared to placebo, in combination with a 26-week glucocorticoid (GC) taper regimen, in adult participants with new-onset or relapsing giant cell arteritis (GCA).
Giant cell arteritis (GCA) is a non-necrotizing granulomatous systemic vasculitis of unknown etiology affecting medium-sized and large arteries usually accompanied or preceded by systemic inflammation. Guselkumab is a monoclonal antibody (mAb) that binds to the p19 sub-unit of human interleukin (IL)-23 with high affinity and blocks binding of extracellular IL-23 to cell surface IL-23 receptor, inhibiting IL 23 specific intracellular signaling and subsequent activation and cytokine production. It is used in treatment of psoriatic arthritis, generalized pustular psoriasis, erythrodermic psoriasis. The study consists of a screening period (less than or equal to [\<=] 6 weeks), double-blind treatment period (48 weeks), and safety follow-up period (12 weeks). Participants who complete the Week 52 visit and are assessed to be in glucocorticoid (GC)-free remission, may have the option to participate in the long-term extension (LTE) period of the study for up to 12 months. This study will evaluate the efficacy, safety, Pharmacokinetics (PK), and immunogenicity of guselkumab in combination with a 26-week GC taper regimen for the treatment of active new-onset or relapsing GCA in adult participants. The total duration of the study is up to 66 weeks for the main study and for participants that continue in the LTE period, the total study duration will be up to 112 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive guselkumab subcutaneously (SC) every 4 weeks from Week 0 through Wweek 48. This will be in combination with a protocol specified 26-week GC taper. Participants of the long-term extension (LTE) period will continue to receive subcutaneous (SC) injections every 4 weeks starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a Giant cell arteritis (GCA) flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
Drug: Guselkumab
Participants will receive matching placebo SC every 4 weeks from Week 0 through Week 48. This will be in combination with a protocol-specified 26-week GC taper. Participants of the LTE period will continue to receive SC injections every 4 weeks starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a GCA flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
Drug: Placebo
Guselkumab will be administered subcutaneously.
Also known as: Tremfya, CNTO 1959
Matching placebo will be administered subcutaneously.
Main Study: Percentage of Participants Achieving Glucocorticoid (GC)-Free Remission at Week 28
GC free remission at Week 28 was defined as (1) no signs or symptoms of active Giant cell arteritis (GCA) at Week 28; (2) absence of GCA flare from first dose of the study drug through Week 28; and (3) adherence to the protocol specified 26-week GC taper regimen. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
Time frame: Week 28
Main Study: Percentage of Participants Achieving GC-Free Remission at Weeks 28, 32, 36, 40, 44, 48 and 52
GC free remission was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively; (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52; (3) adherence to the protocol specified 26-week GC taper regimen. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
Time frame: Weeks 28, 32, 36, 40, 44, 48 and 52
Main Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of Erythrocyte Sedimentation Rate (ESR) at Weeks 28, 32, 36, 40, 44, 48 and 52
GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52 (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of ESR was defined as ESR less than (\<) 30 millimeter per hour (mm/hr) at Weeks 28, 32, 36, 40, 44, 48 and 52. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
Time frame: Weeks 28, 32, 36, 40, 44, 48 and 52
Main Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of C-Reactive Protein (CRP) at Weeks 28, 32, 36, 40, 44, 48 and 52
GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active Giant cell arteritis (GCA) at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52 (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of CRP is defined as CRP \<10 milligrams per liter (mg/L) or \<1 milligrams per deciliter (mg/dL). GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
Time frame: Weeks 28, 32, 36, 40, 44, 48 and 52
Main Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of Both ESR and CRP at Weeks 28, 32, 36, 40, 44, 48 and 52
GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively; (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52; (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of ESR is defined as ESR \< 30 mm/hr at Weeks 28, 32, 36, 40, 44, 48 and 52. Normalization of CRP is defined as CRP \<10 mg/L or \<1 mg/dL. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
Time frame: Weeks 28, 32, 36, 40, 44, 48 and 52
Main Study: Cumulative Glucocorticoid (GC) Dose
Total cumulative GC dose administered included GCA taper, GC rescue therapy as well as for all other indications (any oral GC) from baseline (Day 1) up to Weeks 28 and 52 was reported.
Time frame: Baseline (Day 1) up to Weeks 28 and 52
Main Study: Time to First GCA Disease Flare or Discontinuation of Study Intervention Due to Adverse Event (AE) of Worsening of GCA
Time to occurrence of GCA disease flare was defined as the time from first dose of the study agent to the occurrence of the first observation of GCA disease flare or discontinuation due to adverse event (AE) of worsening of GCA. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
Time frame: Baseline (Day 1) up to Week 30 and Week 52
Main Study: Number of Participants With GCA Disease Flares or Discontinuation of Study Intervention Due to AE of Worsening of GCA
Number of participants with GCA disease flares or discontinuation of study intervention due to AE of worsening of GCA were reported. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
Time frame: Baseline (Day 1) up to Week 30 and Week 52
Main Study: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs (including serious and non-serious AEs) were reported. An AE was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.
Time frame: Baseline (Day 1) up to Week 60
Number of Participants With TEAEs by System Organ Class (SOC) With a Frequency Threshold of 5 Percent (%) or More
Number of participants with TEAEs (including serious and non-serious AEs) by SOC with a frequency threshold of 5 percent (%) or more were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.
Time frame: Baseline (Day 1) up to Week 60
Main Study: Number of Participants With Treatment-emergent Serious Adverse Event (SAEs)
Number of participants with treatment emergent SAEs were reported. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurred at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.
Time frame: Baseline (Day 1) up to Week 60
Main Study: Number of Participants With Clinically Significant Abnormalities in Vital Signs
Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significant abnormal vital signs criteria: Pulse rate: \<50 beats per minutes (bpm) and with greater than (\>) 20 bpm decrease from baseline, \>115 bpm and with \>30 bpm increase from baseline; Systolic blood pressure (SBP): \<90 millimeters of mercury \[mmHg\] and with \>30 mmHg decrease from baseline, \>150 mmHg and with \>40 mmHg increase from baseline; Diastolic blood pressure (DBP): \<50 mmHg and with \>20 mmHg decrease from baseline, \>95 mmHg and with \>30 mmHg increase from baseline; Interarm blood pressure: Interarm blood pressure difference greater than or equal to (\>=) 15 mmHg in systolic blood pressure at 3 consecutive visits; Temperature (Temp): \>38.4 Degree Celsius (C) and with \>=1 C increase from baseline; Weight (kilogram \[kg\]): decrease 10 percent (%) from baseline, increase 10% from baseline; Respiratory Rate: \>20 breaths per minute.
Time frame: Baseline (Day 1) up to Week 60
Main Study: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Number of participants with National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade 3 or 4 abnormalities in clinical laboratory tests: hematology and chemistry were reported. Clinical laboratory abnormalities of living participants were assessed as per NCI CTCAE version 5, grades (0-4), where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. As per the discretion of investigator, laboratory abnormalities with NCI CTCAE Grade 3 or 4 were considered clinically significant. Combined data of Grade 3 and 4 abnormalities are reported as planned. Only those categories in which at least 1 participant had data were reported.
Time frame: Baseline (Day 1) up to Week 60
Main Study: Serum Concentrations of Guselkumab
Serum concentrations of Guselkumab over time was reported.
Time frame: Pre-dose and 1 hour post dose on Week 0 (Day 1), Week 4 (Day 28), and Week 8 (Day 56); Week 12 (Day 84), Week 16 (Day 112), Week 28 (Day 196), Week 52 (Day 364)
Main Study: Number of Participants With Antibodies to Guselkumab
Number of participants with antibodies to Guselkumab were reported.
Time frame: Baseline (Day 1) up to Week 28, Week 52
| Milestone | Guselkumab | Placebo |
|---|---|---|
| Started | 35 | 18 |
| Participants enrolled post pa-5 who received placebo matching to guselkumab 200 mg from week 0 | 0 | 11 |
| Participants enrolled post pa-5 who received guselkumab 200 mg from week 0 | 19 | 0 |
| Completed | 22 | 12 |
| Not completed | 13 | 6 |
| Withdrew: Adverse event | 8 | 2 |
| Withdrew: Study terminated by sponsor | 3 | 3 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Milestone | Guselkumab | Placebo |
|---|---|---|
| Started | 9 | 6 |
| Completed | 5 | 3 |
| Not completed | 4 | 3 |
| Withdrew: Study terminated by sponsor | 3 | 2 |
| Withdrew: Adverse event | 1 | 1 |
GC free remission at Week 28 was defined as (1) no signs or symptoms of active Giant cell arteritis (GCA) at Week 28; (2) absence of GCA flare from first dose of the study drug through Week 28; and (3) adherence to the protocol specified 26-week GC taper regimen. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
| Percentage of Participants | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| Main Study: Percentage of Participants Achieving Glucocorticoid (GC)-Free Remission at Week 28 | 40.0 | 33.3 |
GC free remission was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively; (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52; (3) adherence to the protocol specified 26-week GC taper regimen. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
| Percentage of Participants | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| At Week 28 | 40.0 | 33.3 |
| At Week 32 | 34.3 | 33.3 |
| At Week 36 | 34.3 | 33.3 |
| At Week 40 | 34.3 | 33.3 |
| At Week 44 | 34.3 | 33.3 |
| At Week 48 | 31.4 | 27.8 |
| At Week 52 | 25.7 | 27.8 |
GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52 (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of ESR was defined as ESR less than (\<) 30 millimeter per hour (mm/hr) at Weeks 28, 32, 36, 40, 44, 48 and 52. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
| Percentage of Participants | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| At Week 28 | 22.9 | 5.6 |
| At Week 32 | 22.9 | 11.1 |
| At Week 36 | 22.9 | 16.7 |
| At Week 40 | 25.7 | 16.7 |
| At Week 44 | 22.9 | 11.1 |
| At Week 48 | 20.0 | 22.2 |
| At Week 52 | 22.9 | 16.7 |
GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active Giant cell arteritis (GCA) at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52 (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of CRP is defined as CRP \<10 milligrams per liter (mg/L) or \<1 milligrams per deciliter (mg/dL). GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
| Percentage of Participants | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| At Week 28 | 22.9 | 16.7 |
| At Week 32 | 20.0 | 16.7 |
| At Week 36 | 25.7 | 22.2 |
| At Week 40 | 28.6 | 33.3 |
| At Week 44 | 25.7 | 27.8 |
| At Week 48 | 20.0 | 27.8 |
| At Week 52 | 17.1 | 22.2 |
GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively; (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52; (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of ESR is defined as ESR \< 30 mm/hr at Weeks 28, 32, 36, 40, 44, 48 and 52. Normalization of CRP is defined as CRP \<10 mg/L or \<1 mg/dL. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
| Percentage of Participants | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| At Week 28 | 14.3 | 5.6 |
| At Week 32 | 17.1 | 11.1 |
| At Week 36 | 20.0 | 16.7 |
| At Week 40 | 22.9 | 16.7 |
| At Week 44 | 17.1 | 11.1 |
| At Week 48 | 14.3 | 22.2 |
| At Week 52 | 17.1 | 16.7 |
Total cumulative GC dose administered included GCA taper, GC rescue therapy as well as for all other indications (any oral GC) from baseline (Day 1) up to Weeks 28 and 52 was reported.
| Milligrams (mg) | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| Baseline (Day 1) up to Week 28 | 2231.0 (1315 to 4146) | 2205.0 (1736 to 6010) |
| Baseline (Day 1) up to Week 52 | 2418.5 (1315 to 4319) | 2902.1 (1736 to 7345) |
Time to occurrence of GCA disease flare was defined as the time from first dose of the study agent to the occurrence of the first observation of GCA disease flare or discontinuation due to adverse event (AE) of worsening of GCA. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
| Weeks | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| Baseline (Day 1) up to Week 30 | NA (27.71 to NA) | 29.71 (20.14 to NA) |
| Baseline (Day 1) up to Week 52 | NA (27.71 to NA) | 30.07 (20.14 to NA) |
Number of participants with GCA disease flares or discontinuation of study intervention due to AE of worsening of GCA were reported. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.
| Participants | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| Baseline up to Week 30: 1 Flare | 10 | 8 |
| Baseline up to Week 30: 2 Flares | 0 | 0 |
| Baseline up to Week 30: >=3 Flares | 0 | 0 |
| Baseline up to Week 52: 1 Flare | 13 | 7 |
| Baseline up to Week 52: 2 Flares | 3 | 3 |
| Baseline up to Week 52: >=3 Flares | 0 | 0 |
Number of participants with TEAEs (including serious and non-serious AEs) were reported. An AE was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.
| Participants | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| Main Study: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 34 | 17 |
Number of participants with TEAEs (including serious and non-serious AEs) by SOC with a frequency threshold of 5 percent (%) or more were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.
| Participants | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| Infections and infestations | 21 | 11 |
| Musculoskeletal and connective tissue disorders | 19 | 5 |
| Vascular disorders | 18 | 11 |
| Gastrointestinal disorders | 10 | 2 |
| General disorders and administration site conditions | 10 | 6 |
| Nervous system disorders | 9 | 9 |
| Eye disorders | 8 | 3 |
| Respiratory, thoracic and mediastinal disorders | 8 | 4 |
| Skin and subcutaneous tissue disorders | 8 | 1 |
| Injury, poisoning and procedural complications | 7 | 2 |
| Investigations | 6 | 0 |
| Endocrine disorders | 5 | 0 |
| Psychiatric disorders | 4 | 1 |
| Metabolism and nutrition disorders | 3 | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 3 | 1 |
| Cardiac disorders | 2 | 2 |
| Renal and urinary disorders | 2 | 1 |
| Reproductive system and breast disorders | 1 | 1 |
Number of participants with treatment emergent SAEs were reported. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurred at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.
| Participants | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| Main Study: Number of Participants With Treatment-emergent Serious Adverse Event (SAEs) | 6 | 0 |
Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significant abnormal vital signs criteria: Pulse rate: \<50 beats per minutes (bpm) and with greater than (\>) 20 bpm decrease from baseline, \>115 bpm and with \>30 bpm increase from baseline; Systolic blood pressure (SBP): \<90 millimeters of mercury \[mmHg\] and with \>30 mmHg decrease from baseline, \>150 mmHg and with \>40 mmHg increase from baseline; Diastolic blood pressure (DBP): \<50 mmHg and with \>20 mmHg decrease from baseline, \>95 mmHg and with \>30 mmHg increase from baseline; Interarm blood pressure: Interarm blood pressure difference greater than or equal to (\>=) 15 mmHg in systolic blood pressure at 3 consecutive visits; Temperature (Temp): \>38.4 Degree Celsius (C) and with \>=1 C increase from baseline; Weight (kilogram \[kg\]): decrease 10 percent (%) from baseline, increase 10% from baseline; Respiratory Rate: \>20 breaths per minute.
| Participants | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| Pulse rate: <50 bpm and with >20 bpm decrease | 1 | 0 |
| Pulse rate: >115 bpm and with >30 bpm increase | 0 | 0 |
| Systolic BP: <90 mmHg and >30 mmHg decrease | 2 | 0 |
| Systolic BP: >150 mmHg and >40 mmHg increase | 0 | 2 |
| Diastolic BP: <50 mmHg and >20 mmHg decrease | 2 | 0 |
| Diastolic BP: >95 mmHg and >30 mmHg increase | 1 | 1 |
| Interarm BP:BP difference >=15 mmHg in systolic BP | 2 | 2 |
| Temp: >38.4 C and >=1 C increase from baseline | 0 | 0 |
| Weight: Decrease 10% from baseline | 0 | 1 |
| Weight: Increase 10% from baseline | 6 | 2 |
| Respiratory Rate: >20 breaths per minute | 1 | 4 |
Number of participants with National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade 3 or 4 abnormalities in clinical laboratory tests: hematology and chemistry were reported. Clinical laboratory abnormalities of living participants were assessed as per NCI CTCAE version 5, grades (0-4), where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. As per the discretion of investigator, laboratory abnormalities with NCI CTCAE Grade 3 or 4 were considered clinically significant. Combined data of Grade 3 and 4 abnormalities are reported as planned. Only those categories in which at least 1 participant had data were reported.
| Participants | Main Study: Guselkumab | Main Study: Placebo |
|---|---|---|
| Chemistry: Creatinine Increased | 1 | 0 |
| Chemistry: Alanine Aminotransferase Increased | 1 | 0 |
| Hematology: Lymphocyte Count Decreased | 3 | 3 |
Serum concentrations of Guselkumab over time was reported.
| Microgram per milliliter (mcg/mL | Main Study: Guselkumab |
|---|---|
| Pre dose on Week 0 (Day 1) | 0.00 ± 0.000 |
| 1 Hour Post Dose on Week 0 (Day 1) | 130.93 ± 45.522 |
| Pre dose on Week 4 (Day 28) | 11.21 ± 6.616 |
| 1 Hour Post Dose on Week 4 (Day 28) | 150.21 ± 34.952 |
| Pre dose on Week 8 (Day 56) | 19.71 ± 23.002 |
| 1 Hour Post Dose on Week 8 (Day 56) | 127.14 ± 68.157 |
| Week 12 (Day 84) | 19.16 ± 17.831 |
| Week 16 (Day 112) | 15.81 ± 9.644 |
| Week 28 (Day 196) | 12.63 ± 4.824 |
| Week 52 (Day 364) | 12.55 ± 4.701 |
Number of participants with antibodies to Guselkumab were reported.
| Participants | Main Study: Guselkumab |
|---|---|
| Baseline (Day 1) up to Week 28 | 1 |
| Baseline (Day 1) up to Week 52 | 3 |
Collected over Main study: All-Cause Mortality: From Screening (-6 weeks) up to Week 60; SAEs & Other AEs: Baseline (Day 1) up to Week 60. LTE Period: From Week 52 (LTE Week 0) up to Week 112 (LTE Week 60). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Study: Guselkumab | 1/35 (2.9%) | 6/35 (17.1%) | 31/35 (88.6%) |
| Main Study: Placebo | 0/18 (0%) | 0/18 (0%) | 17/18 (94.4%) |
| LTE Period: Guselkumab | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| LTE Period: Placebo | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Main Study: Guselkumab | Main Study: Placebo | LTE Period: Guselkumab | LTE Period: Placebo |
|---|---|---|---|---|
| Abdominal SepsisInfections and infestations | 1/35 | 0/18 | 0/9 | 0/6 |
| UrosepsisInfections and infestations | 1/35 | 0/18 | 0/9 | 0/6 |
| Fractured SacrumInjury, poisoning and procedural complications | 1/35 | 0/18 | 0/9 | 0/6 |
| Alanine Aminotransferase IncreasedInvestigations | 1/35 | 0/18 | 0/9 | 0/6 |
| Aspartate Aminotransferase IncreasedInvestigations | 1/35 | 0/18 | 0/9 | 0/6 |
| Acute Kidney InjuryRenal and urinary disorders | 1/35 | 0/18 | 0/9 | 0/6 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/35 | 0/18 | 0/9 | 0/6 |
| Peripheral Artery StenosisVascular disorders | 1/35 | 0/18 | 0/9 | 0/6 |
| Event | Main Study: Guselkumab | Main Study: Placebo | LTE Period: Guselkumab | LTE Period: Placebo |
|---|---|---|---|---|
| Giant Cell ArteritisVascular disorders | 17/35 | 10/18 | 0/9 | 1/6 |
| HeadacheNervous system disorders | 6/35 | 7/18 | 0/9 | 0/6 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/35 | 1/18 | 2/9 | 2/6 |
| Covid-19Infections and infestations | 8/35 | 5/18 | 0/9 | 0/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/35 | 0/18 | 1/9 | 1/6 |
| Tinea PedisInfections and infestations | 0/35 | 0/18 | 0/9 | 1/6 |
| FallInjury, poisoning and procedural complications | 2/35 | 1/18 | 0/9 | 1/6 |
| DyslipidaemiaMetabolism and nutrition disorders | 0/35 | 0/18 | 0/9 | 1/6 |
| OsteoporosisMusculoskeletal and connective tissue disorders | 0/35 | 1/18 | 0/9 | 1/6 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 0/35 | 1/18 | 0/9 | 1/6 |
| Age, Categorical(Participants) | Guselkumab | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 3 | 9 |
| >=65 years | 29 | 15 | 44 |
| Age, Continuous(years) | Guselkumab | Placebo | Total |
|---|---|---|---|
| Mean | 71.9 ± 7.65 | 70.8 ± 7.14 | 71.5 ± 7.43 |
| Sex: Female, Male(Participants) | Guselkumab | Placebo | Total |
|---|---|---|---|
| Female | 25 | 12 | 37 |
| Male | 10 | 6 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Guselkumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 3 | 11 |
| Not Hispanic or Latino | 27 | 15 | 42 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Guselkumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 35 | 18 | 53 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Guselkumab | Placebo | Total |
|---|---|---|---|
| Belgium | 4 | 0 | 4 |
| Canada | 8 | 4 | 12 |
| France | 3 | 0 | 3 |
| Germany | 2 | 3 | 5 |
| Israel | 3 | 1 | 4 |
| Italy | 5 | 5 | 10 |
| Poland | 2 | 0 | 2 |
| Spain | 8 | 5 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Dec 2020 to primary completion in May 2024, 41 months.
Results were first posted in Jul 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →